# Simpler Grants.gov #RFA-CA-28-004

NCI funding to continue clinical-trial biospecimen bank operations

**Buyer:** National Institutes of Health (NIH)
**Posted:** October 15, 2026
**Respond By:** February 11, 2027
**Identifier:** RFA-CA-28-004
**NAICS:** 621991, 541715

The National Institutes of Health is seeking eligible institutions to continue operating NCI clinical-trial biospecimen banking resources.
- **Government buyer:** National Institutes of Health (NIH), through the National Cancer Institute (NCI).
- **Opportunity:** Continued operation of the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank).
- **Requested work:** Collect, process, store, and distribute clinically annotated human biospecimens from NCI-funded clinical trials for translational cancer research.
  - NCTN banks support biomarker development and validation, correlative studies, and broader scientific discovery.
  - The EET Biobank supports research on investigational agents, including biomarker assays, pharmacokinetic and pharmacodynamic analyses, drug response and resistance, and patient stratification.
- **Eligibility and key requirement:** Limited competition for existing recipients of the specified NCTN or EET Biobank awards. Foreign organizations and foreign components are ineligible; applications to conduct clinical trials are not allowed.
- **Funding:** The opportunity anticipates six awards and $19 million in total program funding.
- **OEMs and vendors:** None identified. No commercial products or priced line items are listed.

### Description

This limited-competition Notice of Funding Opportunity invites eligible organizations to continue two biospecimen banking resources: the NCI National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). The resources collect, process, store, and distribute clinically annotated human biospecimens from NCI-supported clinical trials to enable translational cancer research. NCTN Biobanks support biomarker research and scientific discovery, while the EET Biobank supports early-phase and experimental trials, including studies of drug response and resistance. Clinical trials are not allowed under this opportunity, and only existing recipients of the specified biobank awards are eligible to apply.

[View original listing](https://simpler.grants.gov/opportunity/361134)